Project: A novel topical therapy for Atopic Dermatitis through development of LXR agonists

This project will deliver a novel topical therapy for Atopic Dermatitis (AD). AD is a common, chronic, inflammatory skin disease. A great body of evidence supports Liver X Receptors (LXRs) as a therapeutic target for AD. The DERMAL project will perform lead selection and preclinical development based on a newly identified chemical series of LXR agonists. This project will produce formulated lead compounds that will be ready for clinical trials within 18 months after completion of this project.

Acronym DERMAL (Reference Number: 10449)
Duration 01/10/2016 - 01/10/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner

Number Name Role Country
24104 Lead Pharma Holding BV Coordinator Netherlands
24105 Saretius Ltd. Partner United Kingdom
24106 StratiCELL SA/NV Partner Belgium
24107 BioAdvice AS Partner Denmark
24108 SiSaf Ltd. Partner United Kingdom